Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222048 | 0.90 | EGLN1 (0.38) | MAPK1RXFP1LIPGTP53EGLN1 | |
| SCHEMBL6196014 | 0.88 | MAPK1 (0.42) | MAPK1RXFP1LIPGTP53EGLN1 | |
| SCHEMBL6197307 | 0.84 | EGLN1 (0.44) | EGLN1CYP1A2CYP3A4NR3C1LMNA | |
| SCHEMBL6198591 | 0.81 | EGLN1 (0.49) | EGLN1CNR2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6195899 | 0.81 | MAPK1 (0.43) | MAPK1EGLN1CNR2CYP1A2CYP3A4 | |
| SCHEMBL6195970 | 0.80 | EGLN1 (0.46) | EGLN1CNR2CYP1A2CYP3A4NR3C1 | |
| SCHEMBL6198708 | 0.78 | EGLN1 (0.44) | EGLN1CYP1A2CYP3A4NR3C1LMNA | |
| SCHEMBL6199268 | 0.77 | MAPK1 (0.44) | MAPK1EGLN1CNR2CYP1A2CYP3A4 | |
| SCHEMBL8122619 | 0.76 | NR3C1 (0.43) | EGLN1CNR2CYP1A2CYP3A4NR3C1 | |
| SCHEMBL6197948 | 0.76 | EGLN1 (0.42) | EGLN1CNR2CYP1A2CYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | claimed |
| WO-2004019932-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | claimed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | claimed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-23 | — | — | US | disclosed |
| WO-2004019932-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186131-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | MAPK1 895/4885RXFP1 45/4885LIPG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.